- Home
- IRIX vs HOOK Comparison
IRIX vs HOOK Comparison
Compare IRIX & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- HOOK
- Stock Information
- Founded
- IRIX 1989
- HOOK 2011
- Country
- IRIX United States
- HOOK United States
- Employees
- IRIX N/A
- HOOK N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- HOOK Health Care
- Exchange
- IRIX Nasdaq
- HOOK Nasdaq
- Market Cap
- IRIX 16.5M
- HOOK 15.3M
- IPO Year
- IRIX 1996
- HOOK 2019
- Fundamental
- Price
- IRIX $1.01
- HOOK $1.19
- Analyst Decision
- IRIX
- HOOK Buy
- Analyst Count
- IRIX 0
- HOOK 4
- Target Price
- IRIX N/A
- HOOK $10.67
- AVG Volume (30 Days)
- IRIX 67.3K
- HOOK 61.7K
- Earning Date
- IRIX 08-07-2025
- HOOK 08-07-2025
- Dividend Yield
- IRIX N/A
- HOOK N/A
- EPS Growth
- IRIX N/A
- HOOK N/A
- EPS
- IRIX N/A
- HOOK N/A
- Revenue
- IRIX $48,804,000.00
- HOOK $9,351,000.00
- Revenue This Year
- IRIX $9.61
- HOOK N/A
- Revenue Next Year
- IRIX N/A
- HOOK N/A
- P/E Ratio
- IRIX N/A
- HOOK N/A
- Revenue Growth
- IRIX N/A
- HOOK N/A
- 52 Week Low
- IRIX $0.78
- HOOK $0.72
- 52 Week High
- IRIX $2.41
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- IRIX 61.37
- HOOK 37.08
- Support Level
- IRIX $0.92
- HOOK $1.13
- Resistance Level
- IRIX $1.01
- HOOK $1.25
- Average True Range (ATR)
- IRIX 0.05
- HOOK 0.06
- MACD
- IRIX 0.02
- HOOK -0.01
- Stochastic Oscillator
- IRIX 100.00
- HOOK 26.94
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.